Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, DiNardo CD, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K.
Sperling AS, et al. Among authors: dinardo cd.
Blood. 2022 Oct 20;140(16):1753-1763. doi: 10.1182/blood.2021014956.
Blood. 2022.
PMID: 35512188
Free PMC article.